Supplemental Annuity Collective Trust of NJ Has $5.60 Million Position in Eli Lilly and Company (NYSE:LLY)

Supplemental Annuity Collective Trust of NJ lowered its position in Eli Lilly and Company (NYSE:LLY) by 11.9% during the fourth quarter, Holdings Channel reports. The firm owned 9,600 shares of the company’s stock after selling 1,300 shares during the period. Eli Lilly and Company comprises 1.9% of Supplemental Annuity Collective Trust of NJ’s portfolio, making the stock its 7th largest holding. Supplemental Annuity Collective Trust of NJ’s holdings in Eli Lilly and Company were worth $5,596,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Lipe & Dalton bought a new stake in Eli Lilly and Company in the fourth quarter worth approximately $26,000. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $27,000. Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company during the 3rd quarter valued at $35,000. Optiver Holding B.V. bought a new position in Eli Lilly and Company during the third quarter worth $36,000. Finally, Family CFO Inc acquired a new stake in Eli Lilly and Company in the third quarter worth $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded up $8.64 during midday trading on Friday, reaching $733.51. The company’s stock had a trading volume of 1,998,801 shares, compared to its average volume of 3,021,320. The stock has a market capitalization of $696.95 billion, a P/E ratio of 126.80, a PEG ratio of 1.60 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The firm has a 50 day moving average price of $762.75 and a 200-day moving average price of $664.94. Eli Lilly and Company has a 12-month low of $380.77 and a 12-month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the previous year, the firm earned $2.09 earnings per share. The business’s revenue was up 28.1% on a year-over-year basis. As a group, equities analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a research report on Monday, April 15th. The Goldman Sachs Group increased their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Truist Financial restated a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 22nd. Citigroup increased their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.